Ephedrine alleviates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition and restraining NF-KB signaling

被引:0
|
作者
Tian, Hui [1 ]
Wang, Limei [2 ]
Fu, Taoli [3 ]
机构
[1] Wuhan Hosp Tradit Chinese Med, Dept Pulm Dis, Wuhan 441300, Peoples R China
[2] Wuhan Hosp Tradit Chinese Med, Dept Pharm, Wuhan 441300, Peoples R China
[3] Wuhan Hosp Tradit Chinese Med, Dept Geratol, Wuhan 441300, Peoples R China
来源
JOURNAL OF TOXICOLOGICAL SCIENCES | 2023年 / 48卷 / 10期
关键词
Pulmonary fibrosis; Epithelial-mesenchymal transition; Ephedrine; Inflammation; PATHOGENESIS; SECRETION;
D O I
暂无
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Pulmonary fibrosis is a lethal and progressive pulmonary disorder in human beings. Ephedrine is a compound isolated from Ephedra and plays a regulatory role in inflammatory response. This study focused on the anti-pulmonary fibrosis effect of ephedrine and its potential molecular mechanism. After a mouse model of pulmonary fibrosis was established through bleomycin (BLM) induction, the survival percentage, body weight, and pulmonary index were measured. Hematoxylin-eosin staining and Masson's trichrome staining for lung tissues were performed to observe the pathological alterations. The viability of lung epithelial BEAS-2B cells, intracellular production of reactive oxygen species, and the levels of pro-inflammatory cytokines were examined by cell counting kit-8 assays, 2',7'-dichlorofluorescein diacetate (DCF-DA) staining, and enzyme-linked immunosorbent assay, respectively. Immunofluorescence staining was performed to determine E-cadherin and vimentin expression after BLM or ephedrine treatment. The mRNA and protein levels of cytokeratin-8, E-cadherin, a-SMA, and vimen-tin were subjected to quantitative polymerase chain reaction and immunoblotting. Experimental results revealed that ephedrine treatment rescued the repressive impact of BLM on BEAS-2B cell viability, and ephedrine inhibited BLM-induced overproduction of reactive oxygen species and inflammatory response in BEAS-2B cells. Additionally, ephedrine suppressed epithelial-mesenchymal transition (EMT) process stimulated by BLM treatment, as demonstrated by the reduced a-SMA and vimentin levels together with the increased cytokeratin-8 and E-cadherin levels in BLM + Ephedrine group. In addition, ephedrine inhibited NF-KB and activated Nrf-2 signaling in BLM-treated BEAS-2B cells. Moreover, ephedrine ameliorated pulmonary fibrosis in BLM-induced mice and improved the survival of model mice. In conclusion, ephedrine attenuates BLM-evoked pulmonary fibrosis by repressing EMT process via blocking NF-KB signaling and activating Nrf-2 signaling, suggesting that ephedrine might become a potential anti -pulmonary fibrosis agent in the future.
引用
收藏
页码:547 / 556
页数:10
相关论文
共 50 条
  • [1] Oleanolic Acid Acetate Alleviates Bleomycin-Induced Pulmonary Fibrosis Via Inhibiting Epithelial-Mesenchymal Transition
    Jung, J.
    Jeong, E.
    Hwang, K.
    Park, C.
    Lim, H.
    Kim, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] β-carboline alkaloids attenuate bleomycin induced pulmonary fibrosis in mice through inhibiting NF-kb/p65 phosphorylation and epithelial-mesenchymal transition
    Cui, Yulei
    Jiang, Lei
    Yu, Ruitao
    Shao, Yun
    Mei, Lijuan
    Tao, Yanduo
    JOURNAL OF ETHNOPHARMACOLOGY, 2019, 243
  • [3] Tauroursodeoxycholic acid alleviates pulmonary endoplasmic reticulum stress and epithelial-mesenchymal transition in bleomycin-induced lung fibrosis
    Tong, Bin
    Fu, Lin
    Hu, Biao
    Zhang, Zhi-Cheng
    Tan, Zhu-Xia
    Li, Se-Ruo
    Chen, Yuan-Hua
    Zhang, Cheng
    Wang, Hua
    Xu, De-Xiang
    Zhao, Hui
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [4] Tauroursodeoxycholic acid alleviates pulmonary endoplasmic reticulum stress and epithelial-mesenchymal transition in bleomycin-induced lung fibrosis
    Bin Tong
    Lin Fu
    Biao Hu
    Zhi-Cheng Zhang
    Zhu-Xia Tan
    Se-Ruo Li
    Yuan-Hua Chen
    Cheng Zhang
    Hua Wang
    De-Xiang Xu
    Hui Zhao
    BMC Pulmonary Medicine, 21
  • [5] Isorhamnetin protects against bleomycin-induced pulmonary fibrosis by inhibiting endoplasmic reticulum stress and epithelial-mesenchymal transition
    Zheng, Qing
    Tong, Ming
    Ou, Baiqing
    Liu, Cuizhong
    Hu, Changping
    Yang, Yu
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 43 (01) : 117 - 126
  • [6] Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition
    Han, Qian
    Lin, Lianjun
    Zhao, Beilei
    Wang, Nanping
    Liu, Xinmin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 500 (04) : 839 - 845
  • [7] Osteopontin silencing attenuates bleomycin-induced murine pulmonary fibrosis by regulating epithelial-mesenchymal transition
    Hatipoglu, Omer Faruk
    Uctepe, Eyyup
    Opoku, Gabriel
    Wake, Hidenori
    Ikemura, Kentaro
    Ohtsuki, Takashi
    Inagaki, Junko
    Gunduz, Mehmet
    Gunduz, Esra
    Watanabe, Shogo
    Nishinaka, Takashi
    Takahashi, Hideo
    Hirohata, Satoshi
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [8] Salvianolate can attenuate bleomycin-induced pulmonary epithelial-mesenchymal transition
    Wang, Fangfang
    Jiang, Handong
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [9] Licoricesaponin G2 ameliorates bleomycin-induced pulmonary fibrosis via targeting TNF-α signaling pathway and inhibiting the epithelial-mesenchymal transition
    Ma, Jing
    Ding, Lu
    Zang, Xiaoyu
    Wei, Ruonan
    Yang, Yingying
    Zhang, Wei
    Su, Hang
    Li, Xueyan
    Li, Min
    Sun, Jun
    Zhang, Zepeng
    Wang, Zeyu
    Zhao, Daqing
    Li, Xiangyan
    Zhao, Linhua
    Tong, Xiaolin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells
    Duan, Jia-Xi
    Guan, Xin-Xin
    Yang, Hui-Hui
    Mei, Wen-Xiu
    Chen, Ping
    Tao, Jia-Hao
    Li, Qing
    Zhou, Yong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101